Table 2. Related metabolites that exist at abnormal levels in the urine from MsPGN patients.
| potential biomarkers | RT | VIP | P | FC |
|---|---|---|---|---|
| 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-1-(trimethylsilyl)- | 17.8 | 1.65659 | 0.003453 | 0.954461 |
| Silanediol, dimethyl- | 3.613197 | 1.77836 | 0.004494 | 0.377826 |
| Carbon disulfide | 1.475 | 12.5682 | 3.75E-06 | 0.337784 |
| Carbamic acid, monoammonium salt | 1.141667 | 3.78809 | 0.000125 | 0.187348 |
| Butylated Hydroxytoluene | 22.94167 | 1.43036 | 0.002001 | 0.051647 |
| Thiourea | 1.35 | 1.67009 | 0.00581 | −0.03801 |
| 4-Heptanone | 5.475 | 2.89244 | 0.000125 | −0.48707 |
| 2-Pentanone | 2.3 | 4.78673 | 8.87E-05 | −0.52189 |
| Pyrrole | 3.075 | 2.76819 | 0.000125 | −0.58163 |
Abbreviations: RT, retention time; VIP, variable importance in the projection; FC, fold change, defined as: FC = log10(X2/X1), while X1 denoted the arithmetic mean value of certain metabolite in the control group and X2 denoted the arithmetic mean value in the case group. FC with a positive value indicates that the concentration of certain metabolite is relatively higher in MsPGN patients compared with healthy controls. FC with a negative value indicates that the concentration of certain metabolite is relatively lower in MsPGN patients compared with healthy controls.